A study at The University of Texas MD Anderson Cancer Center reviewed 13
cancer types and provided a molecular understanding of sex effects in
diverse cancers. The research revealed two cancer-type groups associated
with cancer incidence and mortality, suggesting a "pressing need" to
develop sex-specific therapeutic strategies for some cancers.
Using data from The Cancer Genome Atlas, a team led by Han Liang,
Ph.D., associate professor of Bioinformatics and Computational Biology,
found more than half of the genes studied that were related to clinical
practice of cancer treatment showed sex-biased signatures in certain
cancer types.
"Our study helps elucidate the molecular basis for sex disparities in
cancer and lays a critical foundation for the future development of
precision cancer medicine that is sex-specific," said Liang. "This is a
crucial finding as currently, male and female patients with many cancer
types often are treated in a similar way without explicitly considering
their gender.""Special consideration should be given to those in the strong sex-effect
group in terms of both drug development and practice," said Liang. "For
a therapeutic target with a strong sex-biased signature, sex-specific
clinical trials may be more likely to succeed. This new information is
vital as the fundamental issue of sex differences for cancer prevention
and therapy has not been investigated systematically."
No comments:
Post a Comment